{
    "clinical_study": {
        "@rank": "9898", 
        "arm_group": [
            {
                "arm_group_label": "Stage I-Dose Escalation", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Stage II-Cohort-Expansion", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, multicenter, dose-escalation study to assess the safety,\n      tolerability, and pharmacokinetics of GDC-0994 in patients with locally advanced or\n      metastatic solid tumors. Patients will be enrolled in one of two stages: a d ose-escalation\n      stage (Stage I) or the subsequent expansion stage (Stage II). Sta ge I will evaluate the\n      safety, tolerability, and pharmacokinetics of increasing doses of GDC-0994 administered\n      daily. Stage II will gather additional data on sa fety, tolerability, and pharmacokinetics\n      of the recommended dose of GDC-0994 det ermined in Stage I."
        }, 
        "brief_title": "A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumour", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Histologically or cytologically documented, locally advanced or metastatic solid\n             tumors for which standard therapy either does not exist or has proven ineffective or\n             intolerable\n\n          -  Evaluable disease or disease measurable per RECIST 1.1\n\n          -  Life expectancy >= 12 weeks\n\n          -  Adequate hematologic and end organ function\n\n          -  Consent to provide archival tissue\n\n        Exclusion Criteria:\n\n          -  History of prior significant toxicity from another MEK or ERK inhibitor requiring\n             discontinuation of treatment\n\n          -  History of parathyroid disorder or history or malignancy-associated hypercalcemia\n             requiring therapy in the past 6 months\n\n          -  Evidence of visible retinal pathology as assessed by ophthalmologic examination that\n             is considered a risk factor for retinal vein thrombosis or neurosensory retinal\n             detachment\n\n          -  History of glaucoma\n\n          -  Intraocular pressure > 21 mmHg as measured by tonometry\n\n          -  Predisposing factors to retinal vein occlusion, including uncontrolled hypertension,\n             uncontrolled diabetes, uncontrolled hyperlipidemia, and coagulopathy\n\n          -  History of retinal vein occlusion (RVO), neurosensory retinal detachment, or\n             neovascular macular degeneration\n\n          -  Allergy or hypersensitivity to components of the GDC-0994 formulation\n\n          -  Palliative radiotherapy within 2 weeks prior to first dose of study drug treatment in\n             Cycle 1\n\n          -  Experimental therapy within 4 weeks prior to first dose of study drug treatment in\n             Cycle 1\n\n          -  Major surgical procedure or significant traumatic injury within 4 weeks prior to\n             first dose of study drug treatment in Cycle 1, or anticipation of the need for major\n             surgery during the course of study treatment\n\n          -  Prior anti-cancer therapy within 28 days or 5 times the half-life whichever is longer\n\n          -  Current severe, uncontrolled systemic disease\n\n          -  History of clinically significant cardiac dysfunction\n\n          -  Pregnancy, lactation, or breastfeeding\n\n          -  Active autoimmune disease\n\n          -  Inability or unwillingness to swallow pills\n\n          -  Known brain metastases that are untreated, symptomatic, or require therapy to control\n             symptoms\n\n          -  Clinically significant history of liver disease (including cirrhosis), current\n             alcohol abuse, or current known active infection with HIV, hepatitis B virus, or\n             hepatitis C virus\n\n          -  Any condition requiring warfarin or thrombolytic anticoagulants\n\n          -  Uncontrolled ascites requiring weekly large volume paracentesis for 3 consecutive\n             weeks prior to enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "78", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01875705", 
            "org_study_id": "GO28885", 
            "secondary_id": "2013-000566-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "Stage I-Dose Escalation", 
                "description": "Escalating doses of GDC-0994 until maximum tolerated dose is reached", 
                "intervention_name": "GDC-0994", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Stage II-Cohort-Expansion", 
                "description": "Recommended dose determined in Stage I-Dose Escalation phase, until disease progression", 
                "intervention_name": "GDC-0994", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94805"
                    }
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GO28885 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Maximum tolerated dose", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Dose-limiting toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum plasma concentrations", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Pharmacokinetics: Minimum plasma concentrations", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Pharmacokinetics: Time to maximum plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Pharmacokinetics: Apparent terminal elimination half-life", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01875705"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To assess the PD effects of GDC-0994, as measured by changes in molecular biomarkers in pre- and post-treatment tumor tissues\\n", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Objective Response according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Duration of response according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}